28015
document
Anecortave acetate treatment for retinal angiomatous proliferation : a pilot study . PURPOSE The purpose of this study was to evaluate anecortave acetate treatment of retinal angiomatous proliferation ( RAP ) , a neovascular form of age-related macular degeneration , with specific regard to inhibition of neovascularization and maintenance of vision . METHODS Thirty-four patients with RAP with any stage of neovascularization were randomized 1:1:1 for treatment with three different quantities ( 30 mg , 15 mg , 3 mg ) of anecortave acetate sterile suspension for juxtascleral administration . Best-corrected visual acuity ( Early Treatment Diabetic Retinopathy Study chart ) , intraocular pressure measurement , biomicroscopy , funduscopy , digital fluorescein , and indocyanine green angiography were recorded at baseline and at 3 months . A 6-month retreatment interval was established for this study with a follow-up of 12 months . In selected patients optical coherence tomography was performed . The outcomes were mean changes in visual acuity and lesion size at 1 year . RESULTS The detachment of the neurosensory retina and retinal pigment epithelium improved in all eyes , but all neovascular lesions increased in size . Vision loss occurred in the majority of study eyes ( 22 out of 34 eyes , 64.7 % ) independent of the concentration administered . CONCLUSION The results suggest that a posterior juxtascleral injection of anecortave acetate reduces capillary permeability in patients with RAP . However , in spite of improvement of the exudation there is a progression of neovascularization and a significant loss of vision in all these patients . Like other monotherapeutic methods used to treat this variant of neovascular age-related macular degeneration , anecortave acetate alone does not appear to benefit these patients . Future studies should investigate a combination form of therapy .
28016
Intervention_Pharmacological
Anecortave acetate treatment
28017
Intervention_Pharmacological
anecortave acetate treatment
28018
Intervention_Pharmacological
anecortave acetate sterile suspension for juxtascleral administration
28019
Intervention_Pharmacological
anecortave acetate
28020
Intervention_Pharmacological
anecortave acetate
28021
Outcome_Physical
inhibition of neovascularization
28022
Outcome_Physical
maintenance of vision
28023
Outcome_Physical
Best-corrected visual acuity ( Early Treatment Diabetic Retinopathy Study chart )
28024
Outcome_Physical
intraocular pressure measurement
28025
Outcome_Physical
mean changes in visual acuity
28026
Outcome_Physical
lesion size at 1 year
28027
Outcome_Physical
detachment of the neurosensory retina and retinal pigment epithelium
28028
Outcome_Physical
neovascular lesions
28029
Outcome_Physical
Vision loss
28030
Outcome_Physical
capillary permeability
28031
Outcome_Physical
neovascularization
28032
Outcome_Physical
loss of vision